Cargando…

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia

It is of urgent need to understand the safety and effectiveness of novel coronavirus (COVID-19)-inactivated vaccine in patients with hyperlipidemia (HLD). However, data on the safety and immune response of SARS-CoV-2-inactivated vaccine in HLD patients are limited. In this prospective study, 105 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Lei, Liu, YaMing, Guo, Qiao, Jiang, DePeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487380/ https://www.ncbi.nlm.nih.gov/pubmed/37693840 http://dx.doi.org/10.1515/med-2023-0780

Ejemplares similares

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study
por: Guo, Qiao, et al.
Publicado: (2022)

The hyperlipemia of lymphoma-bearing hamsters.
por: Albrink, W. S., et al.
Publicado: (1971)

Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases
por: Yang, Lei, et al.
Publicado: (2023)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

Postprandial Hyperlipemia is an Indication for Additional Risk in Sitosterolemia
por: Ito, Misa, et al.
Publicado: (2018)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination
por: Yin, Di, et al.
Publicado: (2023)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study
por: Wang, Xiaoqi, et al.
Publicado: (2022)

Prevalence of Obesity, Hyperlipemia and Insulin Resistance in Children with Suprasellar Brain Tumors
por: Adachi, Masanori, et al.
Publicado: (2007)

Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
por: Luo, Huan, et al.
Publicado: (2020)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
por: Wang, Ze-Jun, et al.
Publicado: (2020)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia: A protocol for systematic review and meta-analysis
por: Chen, Mingtai, et al.
Publicado: (2020)

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
por: Zeng, Huiqiong, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
por: Keshtkar-Jahromi, Maryam, et al.
Publicado: (2020)

TRITON HYPERLIPEMIA IN DOGS : I. IN VITRO EFFECTS OF THE DETERGENT ON SERUM LIPOPROTEINS AND CHYLOMICRONS
por: Scanu, Angelo, et al.
Publicado: (1961)

SUSTAINED HYPERLIPEMIA INDUCED IN RABBITS BY MEANS OF INTRAVENOUSLY INJECTED SURFACE-ACTIVE AGENTS
por: Kellner, Aaron, et al.
Publicado: (1951)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
por: Zhang, Yuntao, et al.
Publicado: (2022)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
por: Zheng, Yi-Qing, et al.
Publicado: (2022)

Safety, Immunogenicity and Duration of Immunity Elicited by an Inactivated Bovine Ephemeral Fever Vaccine
por: Aziz-Boaron, Orly, et al.
Publicado: (2013)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
por: Gao, Shuyu, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep
por: Matsiela, Matome Selina, et al.
Publicado: (2023)

The multimorbidity of hypertension and osteoarthritis and relation with sleep quality and hyperlipemia/hyperglycemia in China’s rural population
por: Ran, Li, et al.
Publicado: (2021)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

Severe hyperlipemia-induced pseudoerythrocytosis - Implication for misdiagnosis and blood transfusion: A case report and literature review
por: Zhao, Xi-Chen, et al.
Publicado: (2020)

Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes
por: Fu, Yang, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
por: Wu, Shiheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iefvuqs660hh5qnofvfamt6p09